Apollo.io
CatalystAlert
CatalystAlert
Briefing
Calendar
IPOs
Opportunities
Companies
Compare
Analytics
Watchlist

Search...
Search CatalystAlert
Search for companies, drugs, and catalysts

Search CatalystAlert
Search for companies, drugs, and catalysts


Toggle theme
Sign In
Top Gainers
(24h)
#1
LPTX
$2.05
+368.57%
#2
NBY
$19.16
+183.85%
#3
ZVSA
$0.27
+65.63%
#4
AGL
$0.99
+43.26%
#5
VXRT
$0.68
+41.67%
#6
CHTH
$5.21
+38.93%
#7
ZNTL
$3.74
+31.69%
#8
CGON
$54.20
+29.26%
#9
SLRX
$0.84
+29.23%
#10
MLTX
$18.49
+28.94%
#1
LPTX
$2.05
+368.57%
#2
NBY
$19.16
+183.85%
#3
ZVSA
$0.27
+65.63%
#4
AGL
$0.99
+43.26%
#5
VXRT
$0.68
+41.67%
#6
CHTH
$5.21
+38.93%
#7
ZNTL
$3.74
+31.69%
#8
CGON
$54.20
+29.26%
#9
SLRX
$0.84
+29.23%
#10
MLTX
$18.49
+28.94%
#1
LPTX
$2.05
+368.57%
#2
NBY
$19.16
+183.85%
#3
ZVSA
$0.27
+65.63%
#4
AGL
$0.99
+43.26%
#5
VXRT
$0.68
+41.67%
#6
CHTH
$5.21
+38.93%
#7
ZNTL
$3.74
+31.69%
#8
CGON
$54.20
+29.26%
#9
SLRX
$0.84
+29.23%
#10
MLTX
$18.49
+28.94%

Top Losers
(24h)
#1
SXTC
$0.15
-87.92%
#2
PASW
$0.20
-67.65%
#3
SONN
$1.26
-59.35%
#4
MHUA
$7.61
-45.72%
#5
AQST
$3.91
-37.04%
#6
ATRA
$13.67
-21.62%
#7
GRI
$0.23
-20.77%
#8
PRQR
$1.77
-15.71%
#9
ESLA
$1.20
-14.89%
#10
CDIO
$2.05
-14.58%
#1
SXTC
$0.15
-87.92%
#2
PASW
$0.20
-67.65%
#3
SONN
$1.26
-59.35%
#4
MHUA
$7.61
-45.72%
#5
AQST
$3.91
-37.04%
#6
ATRA
$13.67
-21.62%
#7
GRI
$0.23
-20.77%
#8
PRQR
$1.77
-15.71%
#9
ESLA
$1.20
-14.89%
#10
CDIO
$2.05
-14.58%
#1
SXTC
$0.15
-87.92%
#2
PASW
$0.20
-67.65%
#3
SONN
$1.26
-59.35%
#4
MHUA
$7.61
-45.72%
#5
AQST
$3.91
-37.04%
#6
ATRA
$13.67
-21.62%
#7
GRI
$0.23
-20.77%
#8
PRQR
$1.77
-15.71%
#9
ESLA
$1.20
-14.89%
#10
CDIO
$2.05
-14.58%
AI-Powered Biotech Intelligence
Never Miss a Biotech Catalyst
Track PDUFA dates, Phase 3 results, and FDA decisions for 1,311+ biotech stocks. ML predictions with 82.7% accuracy help you time your entries.

View Catalyst Calendar
Best Entry Timing
Data updated 2m ago

1,311
Biotech Companies
8,113
Drug Pipelines
2,238
Upcoming Catalysts
82.7%
ML Accuracy
Upcoming Catalysts
The next big biotech events

View All
Jan 12, 2026
AZN
Phase 2
Durvalumab Phase 2 Results Expected

AstraZeneca PLC

Jan 12, 2026
MRK
⭐
Phase 3
pembrolizumab Phase 3 Results Expected

MERCK

Jan 15, 2026
LLY
Phase 2
Tirzepatide Phase 2 Results Expected

Eli Lilly and Company

Jan 15, 2026
IMVT
Phase 2
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly Phase 2 Results Expected

Immunovant, Inc.

Jan 15, 2026
JNGHF
Phase 2
HRS-6213 Phase 2 Results Expected

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Recent Results
Latest FDA decisions and trial outcomes

View All
VNDA
approved
FDA PDUFA Date Hetlioz (standard)

Vanda Pharmaceuticals Inc.

SAN.PA
approved
FDA PDUFA Date Tirzepatide (standard)

Sanofi

OMER
approved
FDA PDUFA Date OMIDRIA (standard)

Omeros Corporation

IONS
approved
FDA PDUFA Date inotersen (standard)

Ionis Pharmaceuticals, Inc.

RYTM
approved
FDA PDUFA Date IMCIVREE (priority)

RHYTHM PHARMACEUTICALS, INC.

AI-Powered Analytics
Make Smarter Investment Decisions
Our machine learning models analyze thousands of clinical trials and FDA decisions to predict outcomes and help you understand the biotech landscape.

XGBoost Model
Stock Impact Prediction
Predict potential stock price movement based on upcoming catalysts
Directional prediction (up/down/neutral)
Confidence score with key factors
Trained on 880+ catalyst patterns
Random Forest
Trial Success Probability
Estimate likelihood of approval based on trial characteristics
Phase-specific success rates
Therapeutic area benchmarks
Designation impact analysis
BIO 2024 Data
Industry Benchmarks
Compare against industry-wide success rates and averages
Phase transition success rates
Therapeutic area LOA data
Historical trend analysis
Clinical Phase Success Rates
Industry averages for phase transitions (BIO 2024)
Phase 1 → 2
63.2%
Phase 2 → 3
30.7%
Phase 3 → NDA
58.1%
NDA → Approval
85.3%
Source: BIO Industry Analysis 2024

Likelihood of Approval by Area
Overall LOA from Phase 1 to approval by therapeutic area
26.1%
Hematology
19.1%
Infectious Disease
7.9%
Oncology
8.2%
Neurology
9.4%
Cardiovascular
15.3%
Autoimmune
Higher rates indicate historically better approval odds

How Our ML Works
Data-Driven Predictions You Can Trust
1. Data Collection: We collect historical data from ClinicalTrials.gov, FDA decisions, and market data.

2. Feature Engineering: Our models analyze phase, therapeutic area, designations, market cap, and more.

3. Model Training: XGBoost for impact prediction, Random Forest for LOA - calibrated for accurate probabilities.

4. Continuous Learning: Models retrain weekly with new outcomes to improve accuracy.

ML Service Active
Impact: xgb-v20260111_030112

LOA: rf-v202601090400

Explore Analytics
Predictions are for informational purposes only and NOT financial advice. Past performance does not guarantee future results. Always conduct your own research and consult a financial advisor before making investment decisions.

Everything You Need
Professional biotech intelligence for serious investors

Catalyst Calendar
Interactive calendar with all upcoming FDA dates and trial readouts
ML Predictions
AI-powered stock impact and entry timing predictions (82.7% accuracy)
Entry Timing
Optimal entry points calculated from historical catalyst patterns
Real-time Alerts
Push notifications for catalyst results and watchlist updates
Why CatalystAlert?
Real-time Updates
Data synced daily from ClinicalTrials.gov, SEC filings, and FDA announcements

Official Sources
All data comes directly from government databases and official company filings

Tiered Access
Free tier for browsing, premium tiers unlock ML predictions and alerts

Data Sources
ClinicalTrials.gov - Clinical trial phases and timelines
SEC EDGAR - 8-K filings and press releases
FDA openFDA - Drug approvals and PDUFA dates
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
your@email.com
Subscribe to Alerts
Weekly digest every Monday. Unsubscribe anytime.

Start Trading Smarter
Join thousands of biotech traders using AI-powered predictions to time their entries. Free tier available, upgrade anytime for ML predictions and alerts.

View Calendar
View Pricing
C
CatalystAlert
Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links
This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget
Legal
About
ML Track Record
Privacy
Terms
Data Sources
ClinicalTrials.gov
SEC EDGAR
FDA
⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2026 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.


Feedback
CatalystAlert - Free Biotech Catalyst Calendar with AI Predictions